Showing results (441-450 of 1,028) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.
The Lancet. Respiratory Medicine|April 13, 2019
Functional effects of the microbiota in chronic respiratory diseaseKurtis F Budden, Shakti D Shukla, Saima Firdous Rehman, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
The Lancet. Respiratory Medicine|February 24, 2023
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trialsAlain Amstutz, Benjamin Speich, France Mentré, et al.
The Lancet. Respiratory Medicine|February 26, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trialsAhmet Z Uluer, Gordon MacGregor, Pilar Azevedo, et al.
The Lancet. Respiratory Medicine|February 26, 2025
In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational studyMaria Elena De Piero, Silvia Mariani, Bas C T van Bussel, et al.
The Lancet. Respiratory Medicine|February 13, 2025
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trialMario Castro, Alberto Papi, Celeste Porsbjerg, et al.
The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.
The Lancet. Respiratory Medicine|January 24, 2025
PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trialScott M Norberg, Janet Valdez, Scott Napier, et al.
Pageof 103